Lataa...
Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines
Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor,...
Tallennettuna:
| Julkaisussa: | Mol Pharm |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4783219/ https://ncbi.nlm.nih.gov/pubmed/26824142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.5b00447 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|